NCT07218796Phase 3Recruiting

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Study sponsor: SpyGlass Pharma, Inc. · SGP

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-05-31Estimated

Enrollment · participants400Estimated

Source updated2025-10-20Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Cataract; Glaucoma; Ocular Hypertension

Treatments or interventions studied

Bimatoprost Implant SystemDrug
Timolol Maleate Ophthalmic Solution, 0.5%Drug

Primary outcomes · main study measures

measure: Mean IOP Reduction from Baseline (mmHg); description: Time-matched mean IOP change from Baseline in the study eyes at all the individual IOP timepoints; timeFrame: Weeks 2 and 6, and Month 3; measure: BCDVA 20/40 or better; description: Study eyes achieving best corrected distance visual acuity (BCDVA) of 20/40 or better; timeFrame: Month 6

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history